top of page
Executive Spotlights

Genesis Therapeutics Closes Oversubscribed $200M Series B

Burlingame, CA, August 21, 2023 (Business Wire) -- Genesis Therapeutics, a pioneering company at the forefront of leveraging artificial intelligence (AI) technologies to revolutionize the drug development of cutting-edge treatments for severe diseases, has successfully concluded an oversubscribed Series B financing round, raising $200 million in funding. With this substantial injection of capital, Genesis is poised to advance its AI-enabled programs into clinical development, bolster its advanced AI platform, and aggressively broaden its portfolio of groundbreaking therapeutic discoveries.

Read full article here.

Recent Posts

See All
Life Science Headlines
bottom of page